Physician Split on Obesity Treatment Platforms: LillyDirect Favored by Endocrinologists, NovoCare by PCPs

Event summary

  • Spherix Global Insights surveyed 102 physicians in April 2026, revealing specialty-specific preferences for direct-to-patient obesity treatment platforms.
  • LillyDirect is preferred by 92% of endocrinologists and 90% of PCPs, while NovoCare is used by 75% of endocrinologists and 59% of PCPs.
  • Endocrinologists favor LillyDirect for visibility and administrative support, while PCPs prefer NovoCare for EHR integration and ease of use.
  • 22% of PCPs and 12% of endocrinologists work as telehealth contractors, citing expanded patient reach and improved medication access.
  • Insurance-related administrative burden remains a persistent pain point across both platforms.

The big picture

The obesity treatment landscape is rapidly evolving with direct-to-patient platforms and telehealth partnerships reshaping care delivery. Physician preferences for LillyDirect and NovoCare highlight the need for specialty-specific solutions, while persistent administrative challenges signal opportunities for innovation in reimbursement workflows. The divergence in platform adoption underscores the importance of aligning access channels with physician workflows to maximize patient reach and treatment efficiency.

What we're watching

Platform Differentiation
Whether Lilly and Novo Nordisk can sustain specialty-specific platform advantages amid evolving physician needs.
Telehealth Integration
The pace at which telehealth partnerships will expand physician reach and reshape obesity treatment workflows.
Administrative Innovation
How platforms will address insurance-related administrative burdens to improve physician satisfaction.